These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 9209198

  • 21. Increased urinary N-telopeptide cross-linked type 1 collagen predicts bone loss in patients with inflammatory bowel disease.
    Dresner-Pollak R, Karmeli F, Eliakim R, Ackerman Z, Rachmilewitz D.
    Am J Gastroenterol; 2000 Mar; 95(3):699-704. PubMed ID: 10710060
    [Abstract] [Full Text] [Related]

  • 22. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI.
    JAMA; 1996 Nov 06; 276(17):1389-96. PubMed ID: 8892713
    [Abstract] [Full Text] [Related]

  • 23. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ, MK-677/Alendronate Study Group.
    J Clin Endocrinol Metab; 2001 Mar 06; 86(3):1116-25. PubMed ID: 11238495
    [Abstract] [Full Text] [Related]

  • 24. Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis.
    Dane C, Dane B, Cetin A, Erginbas M.
    Gynecol Endocrinol; 2007 Jul 06; 23(7):398-403. PubMed ID: 17701771
    [Abstract] [Full Text] [Related]

  • 25. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.
    Lems WF, Lodder MC, Lips P, Bijlsma JW, Geusens P, Schrameijer N, van de Ven CM, Dijkmans BA.
    Osteoporos Int; 2006 Jul 06; 17(5):716-23. PubMed ID: 16463007
    [Abstract] [Full Text] [Related]

  • 26. Urinary excretion of type I collagen crosslinked N-telopeptides in healthy Japanese adults: age- and sex-related changes and reference limits.
    Sone T, Miyake M, Takeda N, Fukunaga M.
    Bone; 1995 Oct 06; 17(4):335-9. PubMed ID: 8573404
    [Abstract] [Full Text] [Related]

  • 27. Additive effect of alfacalcidol on bone mineral density of the lumbar spine in Taiwanese postmenopausal women treated with hormone replacement therapy and calcium supplementation: a randomized 2-year study.
    Chen M, Chow SN.
    Clin Endocrinol (Oxf); 2001 Aug 06; 55(2):253-8. PubMed ID: 11531934
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Evaluation of ability of biochemical markers of bone turnover to predict a response to increased doses of HRT.
    Rosen HN, Parker RA, Greenspan SL, Iloputaife ID, Bookman L, Chapin D, Perlmutter I, Kessel B, Qvist P, Rosenblatt M.
    Calcif Tissue Int; 2004 May 06; 74(5):415-23. PubMed ID: 14961215
    [Abstract] [Full Text] [Related]

  • 31. Serum CrossLaps for monitoring the response in individuals undergoing antiresorptive therapy.
    Christgau S, Bitsch-Jensen O, Hanover Bjarnason N, Gamwell Henriksen E, Qvist P, Alexandersen P, Bang Henriksen D.
    Bone; 2000 May 06; 26(5):505-11. PubMed ID: 10773591
    [Abstract] [Full Text] [Related]

  • 32. Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial.
    Khan AA, Bilezikian JP, Kung AW, Ahmed MM, Dubois SJ, Ho AY, Schussheim D, Rubin MR, Shaikh AM, Silverberg SJ, Standish TI, Syed Z, Syed ZA.
    J Clin Endocrinol Metab; 2004 Jul 06; 89(7):3319-25. PubMed ID: 15240609
    [Abstract] [Full Text] [Related]

  • 33. Randomized trial comparing low-dose hormone replacement therapy and HRT plus 1alpha-OH-vitamin D3 (alfacalcidol) for treatment of postmenopausal bone loss.
    Mizunuma H, Shiraki M, Shintani M, Gorai I, Makita K, Itoga S, Mochizuki Y, Mogi H, Iwaoki Y, Kosha S, Yasui T, Ishihara O, Kurabayashi T, Kasuga Y, Hayashi K.
    J Bone Miner Metab; 2006 Jul 06; 24(1):11-5. PubMed ID: 16369892
    [Abstract] [Full Text] [Related]

  • 34. Monitoring of alendronate treatment and prediction of effect on bone mass by biochemical markers in the early postmenopausal intervention cohort study.
    Ravn P, Hosking D, Thompson D, Cizza G, Wasnich RD, McClung M, Yates AJ, Bjarnason NH, Christiansen C.
    J Clin Endocrinol Metab; 1999 Jul 06; 84(7):2363-8. PubMed ID: 10404804
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Peripheral quantitative computed tomography (pQCT) is useful for monitoring bone mineral density of the patients who receive hormone replacement therapy.
    Sawada K, Morishige K, Ohmichi M, Nishio Y, Yamamoto T, Hayakawa J, Mabuchi S, Isobe A, Sasaki H, Sakata M, Tasaka K, Murata Y.
    Maturitas; 2007 Apr 20; 56(4):343-9. PubMed ID: 17010541
    [Abstract] [Full Text] [Related]

  • 37. Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women.
    Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH.
    Osteoporos Int; 2005 Apr 20; 16(4):372-9. PubMed ID: 15654581
    [Abstract] [Full Text] [Related]

  • 38. Evaluation of urinary N-telopeptide of type I collagen measurements in the management of osteoporosis in clinical practice.
    Baxter I, Rogers A, Eastell R, Peel N.
    Osteoporos Int; 2013 Mar 20; 24(3):941-7. PubMed ID: 22872068
    [Abstract] [Full Text] [Related]

  • 39. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
    Stanosz S, Zochowska E, Safranow K, Sieja K, Stanosz M.
    Metabolism; 2009 Jan 20; 58(1):1-7. PubMed ID: 19059524
    [Abstract] [Full Text] [Related]

  • 40. Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers.
    Gallagher JC, Rapuri PB, Haynatzki G, Detter JR.
    J Clin Endocrinol Metab; 2002 Nov 20; 87(11):4914-23. PubMed ID: 12414850
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.